Asparaginase is indicated as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adults.
For this indication, competent medicine agencies globally authorize below treatments:
5,000 - 5,000 [iU] per m² of body surface area (BSA)
From 5,000 To 5,000 [iU] per m² of body surface area (BSA) once every 3 day(s)
Asparaginase is usually employed as part of combination chemotherapy protocols with other antineoplastic agents.
The recommended intravenous dose of asparaginase is 5,000 units per square metre (U/m²) body surface area (BSA) given every third day.
Treatment may be monitored based on the trough serum asparaginase activity measured three days after administration of asparaginase. If asparaginase activity values fail to reach target levels, a switch to a different asparaginase preparation could be considered.
Data on efficacy and safety of asparaginase in adults are limited.
Data on efficacy and safety of asparaginase in the post-induction treatment phases are very limited.
The diluted solution of asparaginase may be infused over 0.5 to 2 hours.